ter international trial. Presented at the 36th annual NCDEU meeting. Boca Raton, FL, May 1996.
35.Beasley CM, Tran P, Tamura RN, et al. Olanzapine versus haloperidol: results of the multi-center international trial. Presented at the 35th Annual Meeting of the ACNP, San Juan, PR, December 1996.
36.Street JS, Tamura R, Sanger T, Tollefson G. Long-term treatmentemergent dyskinetic symptoms in patients treated with olanzapine and haloperidol. Presented at the 36th Annual NCDEU "Meeting. Boca Raton, FL, May 1996.
37.Schooler NR, Kane JM.
Research diagnosis
for tar-dive dyskinesia. Arch Gen Psychiatry 1982; 39: 486-487.
38.Skarsfeldt T. Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurones in rats: acute and repeated treatment. Synapse 1992; 10: 25-33.
39.Costa JF, Cutler NR, Sramek JJ, et al. Rapid dose-escalating safety, tolerability and pharmacokinetic
study of sertindole 4 to 24 mg in schizophrenic patients. Presented at the 156th Annual Meeting of the American Psychiatric Association. New York, NY, May 1996.
40. McEvoy J, Borison R, Small J, et al. The efficacy and tolerability of sertindole in schizophrenic patients: a pilot, double-blind, placebo-controlled, dose ranging study. Schizophr Res 1993; 9 (2, 3): 244.
41.Van Kammen DP, McEvoy JP, Targum SD, et al. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology 1996; 124:168175.
42.Daniel DG, Schmitz PJ, Holgate KL, et al. Two openlabel, long-term safety studies of sertindole. Presented at the 156th Annual Meeting of the American Psychiatric Association. New York, NY, May 1996.
43.Daniel D, Targum S, Zimbroff 0, et al. Efficacy, safety and dose response of three doses of sertindole and three doses of Haldol
in schizophrenia patients. Presented at th 34th Annual Meeting of the AGNP. San Juan, PR, December 1995.
44. Zimbroff DL, Mack RJ, Zborowski JG, et al. Efficacy and safety of three doses of sertindole and three doses of haloperidol in schizophrenic patients. Presented at the 156th Annual Meeting of the American Psychiatric Association. New York, NY, May 1996.
45. Borison RL, Arvanitis LA, Miller BG, et al. ICI 204.636, an atypical antipsychotic: efficacy and